+47.6%
GSK vs EFV
+88.7%
-41.1%
-28.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | EFV | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.2% | -0.9% | +1.1% | +0.8% |
| 7D | -3.6% | -0.5% | -3.1% | -3.3% |
| 30D | -5.9% | 0.0% | -5.9% | -5.9% |
| 3M | -4.3% | +8.4% | -12.7% | -9.2% |
| 6M | -10.8% | +12.3% | -23.1% | -17.4% |
| YTD | +1.8% | +17.4% | -15.6% | -8.4% |
| 1Y | +23.5% | +27.1% | -3.7% | +5.6% |
| All | +47.6% | +88.7% | -41.1% | +3.8% |
Cumulative growth
Daily Returns
Daily percentage return beside EFV.
Daily Out/Under-Performance
Portfolio return minus EFV return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × EFV return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded EFV wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling